Shandong Sinobioway Biomedicine Co Ltd (002581) — Working Capital to Net Assets Ratio
Shandong Sinobioway Biomedicine Co Ltd (002581) has a Working Capital to Net Assets ratio of 30.0% as of September 2025. Working capital of CN¥597.91 Million (current assets of CN¥784.85 Million minus current liabilities of CN¥186.94 Million) is measured against net assets of CN¥1.99 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Shandong Sinobioway Biomedicine Co Ltd (002581) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shandong Sinobioway Biomedicine Co Ltd Working Capital to Net Assets (2007–2024)
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 30.0%, reflecting working capital of CN¥597.91 Million against net assets of CN¥1.99 Billion CNY. Check Shandong Sinobioway Biomedicine Co Ltd (002581) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Shandong Sinobioway Biomedicine Co Ltd market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 32.9% | CN¥664.40 Million | CN¥2.02 Billion | CN¥747.01 Million | CN¥82.61 Million | ▲ +16.1 pp |
| 2023 | 16.7% | CN¥363.10 Million | CN¥2.17 Billion | CN¥496.71 Million | CN¥133.61 Million | ▲ +10.5 pp |
| 2022 | 6.2% | CN¥154.08 Million | CN¥2.47 Billion | CN¥518.36 Million | CN¥364.28 Million | ▼ -6.3 pp |
| 2021 | 12.6% | CN¥309.91 Million | CN¥2.47 Billion | CN¥568.45 Million | CN¥258.54 Million | ▼ -13.0 pp |
| 2020 | 25.5% | CN¥559.30 Million | CN¥2.19 Billion | CN¥766.16 Million | CN¥206.87 Million | ▼ -39.8 pp |
| 2019 | 65.4% | CN¥1.56 Billion | CN¥2.39 Billion | CN¥1.80 Billion | CN¥239.52 Million | ▼ -15.3 pp |
| 2018 | 80.7% | CN¥2.28 Billion | CN¥2.82 Billion | CN¥2.84 Billion | CN¥565.56 Million | ▼ -4.1 pp |
| 2017 | 84.8% | CN¥2.47 Billion | CN¥2.92 Billion | CN¥2.73 Billion | CN¥256.84 Million | ▲ +29.9 pp |
| 2016 | 54.9% | CN¥1.39 Billion | CN¥2.53 Billion | CN¥1.51 Billion | CN¥128.39 Million | ▼ -0.4 pp |
| 2015 | 55.3% | CN¥1.18 Billion | CN¥2.14 Billion | CN¥1.42 Billion | CN¥235.23 Million | ▼ -18.8 pp |
| 2014 | 74.0% | CN¥554.77 Million | CN¥749.40 Million | CN¥572.65 Million | CN¥17.88 Million | ▲ +0.4 pp |
| 2013 | 73.6% | CN¥543.24 Million | CN¥738.31 Million | CN¥576.53 Million | CN¥33.29 Million | ▼ -3.0 pp |
| 2012 | 76.6% | CN¥539.76 Million | CN¥704.41 Million | CN¥562.17 Million | CN¥22.42 Million | ▼ -7.6 pp |
| 2011 | 84.2% | CN¥565.93 Million | CN¥672.28 Million | CN¥583.84 Million | CN¥17.91 Million | ▲ +32.1 pp |
| 2010 | 52.1% | CN¥92.40 Million | CN¥177.34 Million | CN¥124.74 Million | CN¥32.34 Million | ▲ +1.4 pp |
| 2009 | 50.7% | CN¥65.73 Million | CN¥129.71 Million | CN¥100.97 Million | CN¥35.24 Million | ▲ +6.2 pp |
| 2008 | 44.5% | CN¥51.63 Million | CN¥116.12 Million | CN¥79.04 Million | CN¥27.41 Million | ▼ -8.8 pp |
| 2007 | 53.2% | CN¥44.67 Million | CN¥83.94 Million | CN¥56.27 Million | CN¥11.60 Million | — |